Literature DB >> 18356542

Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation.

Samantha J Clarke1, Igor Khaliulin, Manika Das, Joanne E Parker, Kate J Heesom, Andrew P Halestrap.   

Abstract

Inhibition of mitochondrial permeability transition pore (MPTP) opening at reperfusion is critical for cardioprotection by ischemic preconditioning (IP). Some studies have implicated mitochondrial protein phosphorylation in this effect. Here we confirm that mitochondria rapidly isolated from preischemic control and IP hearts show no significant difference in calcium-mediated MPTP opening, whereas IP inhibits MPTP opening in mitochondria isolated from IP hearts following 30 minutes of global normothermic ischemia or 3 minutes of reperfusion. Analysis of protein phosphorylation in density-gradient purified mitochondria was performed using both 2D and 1D electrophoresis, with detection of phosphoproteins using Pro-Q Diamond or phospho-amino-specific antibodies. Several phosphoproteins were detected, including voltage-dependent anion channels isoforms 1 and 2, but none showed significant IP-mediated changes either before ischemia or during ischemia and reperfusion, and neither Western blotting nor 2D fluorescence difference gel electrophoresis detected translocation of protein kinase C (alpha, epsilon, or delta isoforms), glycogen synthase kinase 3beta, or Akt to the mitochondria following IP. In freeze-clamped hearts, changes in phosphorylation of GSK3beta, Akt, and AMP-activated protein kinase were detected following ischemia and reperfusion but no IP-mediated changes correlated with MPTP inhibition or cardioprotection. However, measurement of mitochondrial protein carbonylation, a surrogate marker for oxidative stress, suggested that a reduction in mitochondrial oxidative stress at the end of ischemia and during reperfusion may account for IP-mediated inhibition of MPTP. The signaling pathways mediating this effect and maintaining it during reperfusion are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18356542      PMCID: PMC2629616          DOI: 10.1161/CIRCRESAHA.107.167072

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  54 in total

1.  Analysis of steady-state protein phosphorylation in mitochondria using a novel fluorescent phosphosensor dye.

Authors:  Birte Schulenberg; Robert Aggeler; Joseph M Beechem; Roderick A Capaldi; Wayne F Patton
Journal:  J Biol Chem       Date:  2003-05-20       Impact factor: 5.157

2.  The effects of ischaemic preconditioning, diazoxide and 5-hydroxydecanoate on rat heart mitochondrial volume and respiration.

Authors:  Kelvin H H Lim; Sabzali A Javadov; Manika Das; Samantha J Clarke; M-Saadeh Suleiman; Andrew P Halestrap
Journal:  J Physiol       Date:  2002-12-15       Impact factor: 5.182

3.  Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection.

Authors:  Christopher P Baines; Jun Zhang; Guang-Wu Wang; Yu-Ting Zheng; Joanne X Xiu; Ernest M Cardwell; Roberto Bolli; Peipei Ping
Journal:  Circ Res       Date:  2002-03-08       Impact factor: 17.367

4.  Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes.

Authors:  P Narayan; R M Mentzer; R D Lasley
Journal:  J Mol Cell Cardiol       Date:  2001-01       Impact factor: 5.000

5.  Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress at reoxygenation.

Authors:  Cevher Ozcan; Martin Bienengraeber; Petras P Dzeja; Andre Terzic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-02       Impact factor: 4.733

6.  Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion.

Authors:  T Vanden Hoek; L B Becker; Z H Shao; C Q Li; P T Schumacker
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

7.  Expression of activated PKC epsilon (PKC epsilon) protects the ischemic heart, without attenuating ischemic H(+) production.

Authors:  Heather R Cross; Elizabeth Murphy; Roberto Bolli; Peipei Ping; Charles Steenbergen
Journal:  J Mol Cell Cardiol       Date:  2002-03       Impact factor: 5.000

8.  Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

Authors:  Derek J Hausenloy; Helen L Maddock; Gary F Baxter; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

9.  Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse hearts.

Authors:  Adrian T Saurin; Daniel J Pennington; Nicolaas J H Raat; David S Latchman; Michael J Owen; Michael S Marber
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

10.  Opening of mitochondrial K(ATP) channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning.

Authors:  Yoshito Ohnuma; Tetsuji Miura; Takayuki Miki; Masaya Tanno; Atsushi Kuno; Akihito Tsuchida; Kazuaki Shimamoto
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-07       Impact factor: 4.733

View more
  59 in total

Review 1.  What can we learn about cardioprotection from the cardiac mitochondrial proteome?

Authors:  Marjan Gucek; Elizabeth Murphy
Journal:  Cardiovasc Res       Date:  2010-08-30       Impact factor: 10.787

Review 2.  Regulation and pharmacology of the mitochondrial permeability transition pore.

Authors:  Dmitry B Zorov; Magdalena Juhaszova; Yael Yaniv; H Bradley Nuss; Su Wang; Steven J Sollott
Journal:  Cardiovasc Res       Date:  2009-05-15       Impact factor: 10.787

Review 3.  Role of glycogen synthase kinase-3beta in cardioprotection.

Authors:  Magdalena Juhaszova; Dmitry B Zorov; Yael Yaniv; H Bradley Nuss; Su Wang; Steven J Sollott
Journal:  Circ Res       Date:  2009-06-05       Impact factor: 17.367

Review 4.  Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics.

Authors:  Robert E Gerszten; Aarti Asnani; Steven A Carr
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

5.  Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation.

Authors:  Samarjit Das; Renee Wong; Nishadi Rajapakse; Elizabeth Murphy; Charles Steenbergen
Journal:  Circ Res       Date:  2008-09-18       Impact factor: 17.367

Review 6.  Mitochondrial therapeutics for cardioprotection.

Authors:  Raquel S Carreira; Pamela Lee; Roberta A Gottlieb
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition.

Authors:  Anna W C Leung; Pinadda Varanyuwatana; Andrew P Halestrap
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

8.  Akt and Erk1/2 activate the ornithine decarboxylase/polyamine system in cardioprotective ischemic preconditioning in rats: the role of mitochondrial permeability transition pores.

Authors:  Hao Zhang; Guo Xue; Weihua Zhang; Lina Wang; Hong Li; Li Zhang; Fanghao Lu; Shuzhi Bai; Yan Lin; Yu Lou; Changqing Xu; Yajun Zhao
Journal:  Mol Cell Biochem       Date:  2014-01-24       Impact factor: 3.396

Review 9.  Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection.

Authors:  D Morin; R Assaly; S Paradis; A Berdeaux
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Mitochondrial import of PKCepsilon is mediated by HSP90: a role in cardioprotection from ischaemia and reperfusion injury.

Authors:  Grant R Budas; Eric N Churchill; Marie-Hélène Disatnik; Lihan Sun; Daria Mochly-Rosen
Journal:  Cardiovasc Res       Date:  2010-06-16       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.